<DOC>
	<DOCNO>NCT02503059</DOCNO>
	<brief_summary>Evaluate 3-year survival etanercept patient 60 year psoriasis moderate / severe plaque reason lead abandonment . Besides factor might positive negative influence adherence treatment analysis efficacy ( PASI 75 ) safety identify . All variable collect retrospective review medical record patient dermatology unit make .</brief_summary>
	<brief_title>Etanercept Survival Elderly Population</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients moderate / severe psoriasis ( / without psoriatic arthritis , PAs ) define : PASI ( Psoriasis Area Severity Index ) &gt; 10 / BSA ( Body Surface Area ) &gt; 10 % / DLQI ( Dermatology Life Quality Index ) &gt; 10 PASI &gt; 10 / BSA ( Body Surface Area ) &gt; 10 % / DLQI ( Dermatology Life Quality Index ) &gt; 10 Over 60 year age start treatment Receiving etanercept time Available history Dermatology Patients insufficient clinical data medical record</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>